Login
Home
Charts
Search
Watchlist
Products

Jeena Sikho Lifecare Ltd

JSLL·NSE
524.65+1.79%Wed, 23 Sept '26 14:22

Jeena Sikho Lifecare Ltd

JSLL
NSE
524.65
+1.79%
|Wed, 23 Sept '26 14:22
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
6,515Cr
Close
Close Price
524.15
Industry
Industry
Ayurvedic
PE
Price To Earnings
27.56
PS
Price To Sales
7.65
Revenue
Revenue
851Cr
Rev Gr TTM
Revenue Growth TTM
56.72%
PAT Gr TTM
PAT Growth TTM
102.99%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
114116139174190222216224
Growth YoY
Revenue Growth YoY%
66.491.654.828.8
Expenses
ExpensesCr
7486939698121138132
Operating Profit
Operating ProfitCr
40304679921017892
OPM
OPM%
35.325.632.945.248.545.436.141.0
Other Income
Other IncomeCr
300113314
Interest Expense
Interest ExpenseCr
24324343
Depreciation
DepreciationCr
6891010111615
PBT
PBTCr
3518346979896188
Tax
TaxCr
9591720221622
PAT
PATCr
2713255159674566
Growth YoY
PAT Growth YoY%
120.9404.277.928.5
NPM
NPM%
23.311.418.229.430.930.020.929.4
EPS
EPS
0.40.20.44.14.75.43.65.3
QuarterSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
114116139174190222216224
Growth YoY
Revenue Growth YoY%
66.491.654.828.8
Expenses
ExpensesCr
7486939698121138132
Operating Profit
Operating ProfitCr
40304679921017892
OPM
OPM%
35.325.632.945.248.545.436.141.0
Other Income
Other IncomeCr
300113314
Interest Expense
Interest ExpenseCr
24324343
Depreciation
DepreciationCr
6891010111615
PBT
PBTCr
3518346979896188
Tax
TaxCr
9591720221622
PAT
PATCr
2713255159674566
Growth YoY
PAT Growth YoY%
120.9404.277.928.5
NPM
NPM%
23.311.418.229.430.930.020.929.4
EPS
EPS
0.40.20.44.14.75.43.65.3

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2025Mar 2026TTM
Revenue
RevenueCr
147205469801851
Growth
Revenue Growth%
39.770.856.7
Expenses
ExpensesCr
129159328452489
Operating Profit
Operating ProfitCr
1846141349363
OPM
OPM%
12.322.330.043.642.6
Other Income
Other IncomeCr
137922
Interest Expense
Interest ExpenseCr
11111315
Depreciation
DepreciationCr
33294853
PBT
PBTCr
1544108297316
Tax
TaxCr
411287680
PAT
PATCr
113480222236
Growth
PAT Growth%
199.5177.3103.0
NPM
NPM%
7.616.417.027.727.8
EPS
EPS
11.12.81.317.819.0
Financial YearMar 2022Mar 2023Mar 2025Mar 2026TTM
Revenue
RevenueCr
147205469801851
Growth
Revenue Growth%
39.770.856.7
Expenses
ExpensesCr
129159328452489
Operating Profit
Operating ProfitCr
1846141349363
OPM
OPM%
12.322.330.043.642.6
Other Income
Other IncomeCr
137922
Interest Expense
Interest ExpenseCr
11111315
Depreciation
DepreciationCr
33294853
PBT
PBTCr
1544108297316
Tax
TaxCr
411287680
PAT
PATCr
113480222236
Growth
PAT Growth%
199.5177.3103.0
NPM
NPM%
7.616.417.027.727.8
EPS
EPS
11.12.81.317.819.0

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
10142525
Reserves
ReservesCr
26112231442
Current Liabilities
Current LiabilitiesCr
242573105
Non Current Liabilities
Non Current LiabilitiesCr
1189102
Total Liabilities
Total LiabilitiesCr
62151419674
Current Assets
Current AssetsCr
2277135341
Non Current Assets
Non Current AssetsCr
4074284333
Total Assets
Total AssetsCr
62151419674
Financial YearMar 2022Mar 2023Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
10142525
Reserves
ReservesCr
26112231442
Current Liabilities
Current LiabilitiesCr
242573105
Non Current Liabilities
Non Current LiabilitiesCr
1189102
Total Liabilities
Total LiabilitiesCr
62151419674
Current Assets
Current AssetsCr
2277135341
Non Current Assets
Non Current AssetsCr
4074284333
Total Assets
Total AssetsCr
62151419674

Cash Flow

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
161585254
Investing Cash Flow
Investing Cash FlowCr
-18-33-64-202
Financing Cash Flow
Financing Cash FlowCr
-548-22-59
Net Cash Flow
Net Cash FlowCr
-729-2-7
Free Cash Flow
Free Cash FlowCr
3-1545221
CFO To PAT
CFO To PAT%
146.143.3105.7114.5
CFO To EBITDA
CFO To EBITDA%
90.631.860.172.6
Financial YearMar 2022Mar 2023Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
161585254
Investing Cash Flow
Investing Cash FlowCr
-18-33-64-202
Financing Cash Flow
Financing Cash FlowCr
-548-22-59
Net Cash Flow
Net Cash FlowCr
-729-2-7
Free Cash Flow
Free Cash FlowCr
3-1545221
CFO To PAT
CFO To PAT%
146.143.3105.7114.5
CFO To EBITDA
CFO To EBITDA%
90.631.860.172.6

Ratios

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
40027,1316,7116,515
Price To Earnings
Price To Earnings
11.867.930.327.6
Price To Sales
Price To Sales
1.957.88.47.7
Price To Book
Price To Book
3.221.214.413.9
EV To EBITDA
EV To EBITDA
8.1193.619.317.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
87.687.387.288.588.5
OPM
OPM%
12.322.330.043.642.6
NPM
NPM%
7.616.417.027.727.8
ROCE
ROCE%
36.935.531.752.252.2
ROE
ROE%
30.726.631.247.547.5
ROA
ROA%
18.222.219.132.932.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2022Mar 2023Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
40027,1316,7116,515
Price To Earnings
Price To Earnings
11.867.930.327.6
Price To Sales
Price To Sales
1.957.88.47.7
Price To Book
Price To Book
3.221.214.413.9
EV To EBITDA
EV To EBITDA
8.1193.619.317.5
Profitability Ratios
Profitability Ratios
GPM
GPM%
87.687.387.288.588.5
OPM
OPM%
12.322.330.043.642.6
NPM
NPM%
7.616.417.027.727.8
ROCE
ROCE%
36.935.531.752.252.2
ROE
ROE%
30.726.631.247.547.5
ROA
ROA%
18.222.219.132.932.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Jeena Sikho Lifecare is an integrated Ayurvedic hospital company that treats chronic diseases at their root cause rather than just managing symptoms - and it measures itself against mainstream hospital metrics, not alternative-medicine benchmarks. Born from founder Acharya Manish Ji’s personal health struggles and his two-decade immersion in Ayurveda, the business began as a single Chandigarh clinic in 2013 and transformed into a listed hospital chain after opening its first inpatient facility in 2020. The recurring pattern is a capital-light, doctor-driven model where every patient who recovers becomes a lifelong medicine customer, and every medicine customer is a potential hospital admission - a flywheel that funds its own growth without debt. # Business segments Two engines that feed each other - a network of Ayurvedic hospitals and clinics that treats patients, and a portfolio of over 330 proprietary medicines those patients take home, each generating roughly half the business and each making the other stronger. ## 1. Ayurveda healthcare services: the hospital network that brings patients in **A hub-and-spoke network of 117-119 facilities across 23 states treats chronic lifestyle diseases through Panchakarma detoxification, with setup costs roughly one-tenth of an allopathy hospital and break-even at just 35% occupancy.** - **Cheaper to build than conventional hospitals** - setup cost per bed is only ₹3-4 lakh, compared to ₹50 lakh to ₹1 crore for allopathy hospitals, because Ayurveda needs no expensive imaging machines or surgical theatres. - **Hub-and-spoke keeps costs low** - large hospitals in big cities act as hubs, while clinics in nearby small towns refer patients to them, so the company gets patient flow without putting a full hospital in every town. - **Paid by governments and insurers** - the company is empanelled with CGHS, all seven central armed police forces, ECHS, and major insurers like Star Health and HDFC ERGO, meaning patients can pay cashless rather than out-of-pocket. - **Camps convert visitors into inpatients** - 72-hour health camps generate ₹30-60 lakh each and convert roughly 30% of attendees into hospital admissions, functioning as both a revenue line and a patient-acquisition channel. - **Doctors stay on payroll even in franchises** - in the 33-35 franchise clinics, the franchisee bears the property cost but the company employs the Ayurveda doctors and supplies the medicines, so clinical quality and product revenue stay in-house. ## 2. Ayurvedic products: the medicines patients take home **Over 330 proprietary formulations - all patent medicines, not classical ones - are sold to patients leaving hospitals and to outside customers, with gross margins above 85% and manufacturing entirely outsourced.** - **No factory, no capex** - all manufacturing is done by third-party contractors under loan licenses, so the company avoids tying up capital in plants and carries no manufacturing working-capital burden. - **The hospital feeds the pharmacy** - every discharged patient leaves with a medicine regimen that generates recurring revenue for months or years, and every medicine customer who calls the support centre is a potential hospital admission. - **Priced at a seven-times multiple** - the company’s product costing yields a retail price that is about seven times the cost, which is how the vertical sustains its high gross margins. - **Now reaching patients through Amazon** - a procurement agreement with Theryco Healthcare Solutions in January 2026 authorised listing and selling the company’s products on the Amazon platform, opening a channel beyond its own clinics. - **Even pets are covered** - the ‘Pet Shuddhi’ line, launched nationally in October 2025, offers Ayurvedic detoxification kits for pets’ stomach, liver, and spleen, backed by clinical validation from the company’s own hospitals. # Group structure and partners **A single listed entity with a UAE subsidiary that is already acquiring clinics, a diagnostic partner embedded in every hospital, and a patient-referral collaboration that pays a share of billing.** - **UAE subsidiary is buying, not just building** - Jeena Sikho International LLC, incorporated in Sharjah in September 2025, has approved the proposal for acquisition of a 51% stake in Back to Roots Ayurveda by Dr. Shyam LLC in Abu Dhabi, with a Share Purchase Agreement yet to be executed. - **Diagnostics outsourced to one partner** - Chandan Healthcare Limited has a five-year exclusive agreement to set up and run diagnostic centres inside all Jeena Sikho facilities, investing its own capital in equipment and manpower, while Jeena Sikho provides the space and branding. - **Patient acquisition through a revenue-share deal** - Sat Kartar Life Ltd identifies and funnels patients to Jeena Sikho’s hospitals under a three-year MOU, earning 15% of the bill value on both OPD and IPD cases for as long as the patient remains in active treatment. - **A green subsidiary that has not yet started** - Jeena Green Resources Private Limited, 51%-owned, was incorporated in March 2025 to make organic manure and cow-urine-based Ayurvedic formulations, but had not commenced business as of its filing date.

Documents — Jeena Sikho Lifecare Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/qqj5hb6yb6tdc1mbtzuv81ch.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/51kkqwu3rkp2tndh9ub7t784.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/lrekvbj1qssfyl1b4169jizo.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/rty4g1rpcf24ph3tfnt1vxye.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/g3ig6d5jymedif96x59t8clb.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/i2mitjkydm78ugo2yo265ccf.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/4fhb6j2uz1deagkqijd9zy4b.pdf
  • Q4 FY2024 Earnings Call Transcript (Mar 2024, PDF): https://www.stockscans.in/document/wdhkzq5vortevpkkyvfs3nc2.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/fn9ikv5ci8ndl90m4o0eflv2.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/1wla7na3etr97uoljx3u7flp.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/sl8tovnvtpxpynvrnoxddazh.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/111v8hs73c5al6bech80ttnz.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/m8hsovzc36gm5l76bgh0qavs.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/g4fy9utv8tyggjwndmav63pt.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/f63h9jendo1zem6n0b4rkhnv.pdf
  • Q4 FY2024 Quarterly Result (Mar 2024, PDF): https://www.stockscans.in/document/p9neeb1tuzcgzoub5a0jcv3g.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/7hj3oovxcxv69s3v184iznh3.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/k9l7x0dmkem9fo4in331n5t2.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/tg3onior3mc9pzvztta03uac.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/b534idqvi9z6likx71brdkhs.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/ihuhg3cz074qk7zosf7gcu4j.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/24l4942mtrig92ibdn72whtx.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/mjvmdhew5n8k321mj2g1jwhw.pdf
  • Q4 FY2024 Investor Presentation (Mar 2024, PDF): https://www.stockscans.in/document/xv6vs1mo5qaog1xu6r1pkbrt.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/6m1awstm594rvoetqin41qok.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/x320yqdyfb9jy8gicllc738s.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/pha1myqgeqv9l7byopjyrvly.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/9vdxl6ld4m7kvg2m2tvbi5c9.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/tll8iyc3vp60jkm3ybsujigl.pdf

Concall Transcript Summaries — Jeena Sikho Lifecare Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202606/qqj5hb6yb6tdc1mbtzuv81ch.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202603/51kkqwu3rkp2tndh9ub7t784.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202512/lrekvbj1qssfyl1b4169jizo.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202509/rty4g1rpcf24ph3tfnt1vxye.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202506/g3ig6d5jymedif96x59t8clb.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202503/i2mitjkydm78ugo2yo265ccf.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202409/4fhb6j2uz1deagkqijd9zy4b.pdf
  • Q4 FY2024 Concall Transcript Summary (Mar 2024): https://www.stockscans.in/company/NSE%3AJSLL/transcript-notes/202403/wdhkzq5vortevpkkyvfs3nc2.pdf